Kyongbo Pharmaceutical Co., Ltd
KRX:214390.KS
5150 (KRW) • At close July 30, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) KRW.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 238,556.126 | 216,357.482 | 196,264.902 | 170,659.645 | 215,285.095 | 191,706.189 | 201,343.596 | 191,661.374 | 186,726.17 | 178,032.632 | 169,781.246 |
| Kosten van de omzet
| 156,135.778 | 153,282.206 | 151,847.03 | 135,299.352 | 162,820.355 | 150,990.036 | 152,082.417 | 137,038.683 | 142,622.767 | 129,475.387 | 119,975.881 |
| Brutowinst
| 82,420.348 | 63,075.276 | 44,417.872 | 35,360.293 | 52,464.74 | 40,716.153 | 49,261.178 | 54,622.691 | 44,103.403 | 48,557.245 | 49,805.365 |
| Brutowinstmarge
| 0.345 | 0.292 | 0.226 | 0.207 | 0.244 | 0.212 | 0.245 | 0.285 | 0.236 | 0.273 | 0.293 |
| Onderzoek- en ontwikkelingskosten
| 5,312.433 | 3,653.609 | 3,076.836 | 5,053.263 | 6,238.238 | 1,418.246 | 769.777 | 765.403 | 1,484.458 | 1,866.738 | 1,251.438 |
| Algemene en administratieve kosten
| 2,361.257 | 2,381.395 | 1,913.611 | 2,288.277 | 2,930.524 | 3,979.332 | 3,289.891 | 4,372.12 | 4,434.433 | 3,554.951 | 1,873.968 |
| Verkoop- en marketingkosten
| 44,680.592 | 33,402.085 | 22,122.861 | 17,153.554 | 11,403.958 | 8,874.763 | 8,006.781 | 7,895.982 | 6,425.099 | 5,171.14 | 6,115.969 |
| Verkoop-, algemene en administratieve kosten
| 47,041.849 | 35,783.48 | 24,036.472 | 19,441.831 | 14,334.482 | 12,854.095 | 11,296.672 | 12,268.102 | 10,859.532 | 8,726.091 | 7,989.937 |
| Overige kosten
| 19,612.338 | 18,093.415 | 15,911.912 | 17,490.043 | 23,230.588 | 20,249.739 | 266.627 | 2,191.657 | 778.574 | 648.976 | 3,312.286 |
| Bedrijfskosten
| 71,966.62 | 57,530.504 | 43,025.22 | 41,985.137 | 43,803.308 | 34,522.08 | 31,994.604 | 30,036.042 | 28,509.176 | 22,924.91 | 22,136.802 |
| Bedrijfsresultaat
| 10,453.728 | 5,544.772 | 1,392.652 | -4,595.42 | 5,677.213 | 6,194.073 | 17,266.575 | 24,586.649 | 15,594.227 | 25,632.335 | 27,668.563 |
| Bedrijfsresultaat ratio
| 0.044 | 0.026 | 0.007 | -0.027 | 0.026 | 0.032 | 0.086 | 0.128 | 0.084 | 0.144 | 0.163 |
| Totaal overige inkomsten en kosten netto
| -5,550.688 | -3,372.848 | -2,007.485 | -3,308.103 | 2,399.183 | -1,293.008 | -1,200.948 | -325.611 | -1,496.967 | -100.026 | 1,343.271 |
| Inkomen voor belasting
| 4,903.04 | 2,171.924 | -614.836 | -9,932.947 | 14,030.793 | 6,982.154 | 17,643.548 | 24,261.039 | 15,643.086 | 25,532.309 | 30,034.305 |
| Inkomen voor belasting ratio
| 0.021 | 0.01 | -0.003 | -0.058 | 0.065 | 0.036 | 0.088 | 0.127 | 0.084 | 0.143 | 0.177 |
| Belastingkosten
| 263.715 | -802.476 | -1,225.426 | -2,437.768 | 4,626.346 | 1,696.914 | 4,527.498 | 6,297.729 | 2,937.156 | -577.314 | 21,398.351 |
| Nettowinst
| 4,639.326 | 2,974.4 | 610.59 | -7,495.179 | 9,404.446 | 5,285.239 | 13,116.049 | 17,963.31 | 12,705.93 | 26,109.623 | 8,635.954 |
| Nettowinstmarge
| 0.019 | 0.014 | 0.003 | -0.044 | 0.044 | 0.028 | 0.065 | 0.094 | 0.068 | 0.147 | 0.051 |
| WPA (Winst Per Aandeel)
| 194.06 | 124.42 | 25.54 | -313.52 | 393.38 | 221.08 | 549 | 751 | 531 | 1,147 | 401 |
| Verwaterde WPA
| 194.06 | 124.42 | 25.54 | -313.52 | 393.38 | 221.08 | 549 | 751 | 531 | 1,147 | 401 |
| EBITDA
| 21,600.69 | 17,243.592 | 13,328.388 | 4,212.095 | 21,249.376 | 18,783.228 | 28,824.445 | 36,054.105 | 26,033.974 | 33,910.923 | 34,871.188 |
| EBITDA ratio
| 0.091 | 0.08 | 0.068 | 0.025 | 0.099 | 0.098 | 0.143 | 0.188 | 0.139 | 0.19 | 0.205 |